Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia

Ego Seeman, Jean Pierre Devogelaer, Roman Lorenc, Timothy Spector, Kim Brixen, A. Balogh, Gerold Stucki, Jean Yves Reginster

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Many fractures occur in women with moderate fracture risk caused by osteopenia. Strontium ranelate was studied in 1431 postmenopausal women with osteopenia. Vertebral fracture risk reduction of 41-59% was shown depending on the site and fracture status at baseline. This is the first report of antivertebral fracture efficacy in women with vertebral osteopenia. Introduction: Women with osteoporosis are at high risk for fracture. However, more than one half of all fractures in the community originate from the larger population at more moderate risk of fracture caused by osteopenia. Despite this, evidence for antifracture efficacy in these persons is limited. The aim of this study was to determine whether strontium ranelate, a new drug that reduces fracture risk in women with osteoporosis, is also effective in women with osteopenia. Materials and Methods: Data from the Spinal Osteoporosis Therapeutic Intervention study (SOTI; n = 1649) and the TReatment Of Peripheral Osteoporosis (TROPOS; n = 5091) were pooled to evaluate the antivertebral fracture efficacy of strontium ranelate in women with lumbar spine (LS) osteopenia with any BMD value at the femoral neck (FN; N = 1166) and in 265 women with osteopenia at both sites (intention-to-treat analysis). The women were randomized to strontium ranelate 2 g/d orally or placebo for 3 yr. Results: No group differences were present in baseline characteristics that may influence fracture outcome independent of therapy. In women with LS osteopenia, treatment reduced the risk of vertebral fracture by 41% (RR = 0.59; 95% CI, 0.43-0.82), by 59% (RR = 0.41; 95% CI, 0.17-0.99) in the 447 patients with no prevalent fractures, and by 38% (RR = 0.62; 95% CI, 0.44-0.88) in the 719 patients with prevalent fractures. In women with osteopenia at both sites, treatment reduced the risk of fracture by 52% (RR = 0.48; 95% CI, 0.24-0.96). Conclusions: Strontium ranelate safely reduces the risk of vertebral fractures in women with osteopenia with or without a prevalent fracture.

Original languageEnglish
Pages (from-to)433-438
Number of pages6
JournalJournal of Bone and Mineral Research
Volume23
Issue number3
DOIs
Publication statusPublished - Mar 2008

Fingerprint

strontium ranelate
Metabolic Bone Diseases
Osteoporosis
Spine
Therapeutics

Keywords

  • Osteopenia
  • Strontium ranelate
  • Vertebral fracture risk reduction

ASJC Scopus subject areas

  • Surgery

Cite this

Seeman, E., Devogelaer, J. P., Lorenc, R., Spector, T., Brixen, K., Balogh, A., ... Reginster, J. Y. (2008). Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. Journal of Bone and Mineral Research, 23(3), 433-438. https://doi.org/10.1359/jbmr.071105

Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. / Seeman, Ego; Devogelaer, Jean Pierre; Lorenc, Roman; Spector, Timothy; Brixen, Kim; Balogh, A.; Stucki, Gerold; Reginster, Jean Yves.

In: Journal of Bone and Mineral Research, Vol. 23, No. 3, 03.2008, p. 433-438.

Research output: Contribution to journalArticle

Seeman, E, Devogelaer, JP, Lorenc, R, Spector, T, Brixen, K, Balogh, A, Stucki, G & Reginster, JY 2008, 'Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia', Journal of Bone and Mineral Research, vol. 23, no. 3, pp. 433-438. https://doi.org/10.1359/jbmr.071105
Seeman, Ego ; Devogelaer, Jean Pierre ; Lorenc, Roman ; Spector, Timothy ; Brixen, Kim ; Balogh, A. ; Stucki, Gerold ; Reginster, Jean Yves. / Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. In: Journal of Bone and Mineral Research. 2008 ; Vol. 23, No. 3. pp. 433-438.
@article{3e95ee9daca74a5a8264db48c3bbc32f,
title = "Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia",
abstract = "Many fractures occur in women with moderate fracture risk caused by osteopenia. Strontium ranelate was studied in 1431 postmenopausal women with osteopenia. Vertebral fracture risk reduction of 41-59{\%} was shown depending on the site and fracture status at baseline. This is the first report of antivertebral fracture efficacy in women with vertebral osteopenia. Introduction: Women with osteoporosis are at high risk for fracture. However, more than one half of all fractures in the community originate from the larger population at more moderate risk of fracture caused by osteopenia. Despite this, evidence for antifracture efficacy in these persons is limited. The aim of this study was to determine whether strontium ranelate, a new drug that reduces fracture risk in women with osteoporosis, is also effective in women with osteopenia. Materials and Methods: Data from the Spinal Osteoporosis Therapeutic Intervention study (SOTI; n = 1649) and the TReatment Of Peripheral Osteoporosis (TROPOS; n = 5091) were pooled to evaluate the antivertebral fracture efficacy of strontium ranelate in women with lumbar spine (LS) osteopenia with any BMD value at the femoral neck (FN; N = 1166) and in 265 women with osteopenia at both sites (intention-to-treat analysis). The women were randomized to strontium ranelate 2 g/d orally or placebo for 3 yr. Results: No group differences were present in baseline characteristics that may influence fracture outcome independent of therapy. In women with LS osteopenia, treatment reduced the risk of vertebral fracture by 41{\%} (RR = 0.59; 95{\%} CI, 0.43-0.82), by 59{\%} (RR = 0.41; 95{\%} CI, 0.17-0.99) in the 447 patients with no prevalent fractures, and by 38{\%} (RR = 0.62; 95{\%} CI, 0.44-0.88) in the 719 patients with prevalent fractures. In women with osteopenia at both sites, treatment reduced the risk of fracture by 52{\%} (RR = 0.48; 95{\%} CI, 0.24-0.96). Conclusions: Strontium ranelate safely reduces the risk of vertebral fractures in women with osteopenia with or without a prevalent fracture.",
keywords = "Osteopenia, Strontium ranelate, Vertebral fracture risk reduction",
author = "Ego Seeman and Devogelaer, {Jean Pierre} and Roman Lorenc and Timothy Spector and Kim Brixen and A. Balogh and Gerold Stucki and Reginster, {Jean Yves}",
year = "2008",
month = "3",
doi = "10.1359/jbmr.071105",
language = "English",
volume = "23",
pages = "433--438",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia

AU - Seeman, Ego

AU - Devogelaer, Jean Pierre

AU - Lorenc, Roman

AU - Spector, Timothy

AU - Brixen, Kim

AU - Balogh, A.

AU - Stucki, Gerold

AU - Reginster, Jean Yves

PY - 2008/3

Y1 - 2008/3

N2 - Many fractures occur in women with moderate fracture risk caused by osteopenia. Strontium ranelate was studied in 1431 postmenopausal women with osteopenia. Vertebral fracture risk reduction of 41-59% was shown depending on the site and fracture status at baseline. This is the first report of antivertebral fracture efficacy in women with vertebral osteopenia. Introduction: Women with osteoporosis are at high risk for fracture. However, more than one half of all fractures in the community originate from the larger population at more moderate risk of fracture caused by osteopenia. Despite this, evidence for antifracture efficacy in these persons is limited. The aim of this study was to determine whether strontium ranelate, a new drug that reduces fracture risk in women with osteoporosis, is also effective in women with osteopenia. Materials and Methods: Data from the Spinal Osteoporosis Therapeutic Intervention study (SOTI; n = 1649) and the TReatment Of Peripheral Osteoporosis (TROPOS; n = 5091) were pooled to evaluate the antivertebral fracture efficacy of strontium ranelate in women with lumbar spine (LS) osteopenia with any BMD value at the femoral neck (FN; N = 1166) and in 265 women with osteopenia at both sites (intention-to-treat analysis). The women were randomized to strontium ranelate 2 g/d orally or placebo for 3 yr. Results: No group differences were present in baseline characteristics that may influence fracture outcome independent of therapy. In women with LS osteopenia, treatment reduced the risk of vertebral fracture by 41% (RR = 0.59; 95% CI, 0.43-0.82), by 59% (RR = 0.41; 95% CI, 0.17-0.99) in the 447 patients with no prevalent fractures, and by 38% (RR = 0.62; 95% CI, 0.44-0.88) in the 719 patients with prevalent fractures. In women with osteopenia at both sites, treatment reduced the risk of fracture by 52% (RR = 0.48; 95% CI, 0.24-0.96). Conclusions: Strontium ranelate safely reduces the risk of vertebral fractures in women with osteopenia with or without a prevalent fracture.

AB - Many fractures occur in women with moderate fracture risk caused by osteopenia. Strontium ranelate was studied in 1431 postmenopausal women with osteopenia. Vertebral fracture risk reduction of 41-59% was shown depending on the site and fracture status at baseline. This is the first report of antivertebral fracture efficacy in women with vertebral osteopenia. Introduction: Women with osteoporosis are at high risk for fracture. However, more than one half of all fractures in the community originate from the larger population at more moderate risk of fracture caused by osteopenia. Despite this, evidence for antifracture efficacy in these persons is limited. The aim of this study was to determine whether strontium ranelate, a new drug that reduces fracture risk in women with osteoporosis, is also effective in women with osteopenia. Materials and Methods: Data from the Spinal Osteoporosis Therapeutic Intervention study (SOTI; n = 1649) and the TReatment Of Peripheral Osteoporosis (TROPOS; n = 5091) were pooled to evaluate the antivertebral fracture efficacy of strontium ranelate in women with lumbar spine (LS) osteopenia with any BMD value at the femoral neck (FN; N = 1166) and in 265 women with osteopenia at both sites (intention-to-treat analysis). The women were randomized to strontium ranelate 2 g/d orally or placebo for 3 yr. Results: No group differences were present in baseline characteristics that may influence fracture outcome independent of therapy. In women with LS osteopenia, treatment reduced the risk of vertebral fracture by 41% (RR = 0.59; 95% CI, 0.43-0.82), by 59% (RR = 0.41; 95% CI, 0.17-0.99) in the 447 patients with no prevalent fractures, and by 38% (RR = 0.62; 95% CI, 0.44-0.88) in the 719 patients with prevalent fractures. In women with osteopenia at both sites, treatment reduced the risk of fracture by 52% (RR = 0.48; 95% CI, 0.24-0.96). Conclusions: Strontium ranelate safely reduces the risk of vertebral fractures in women with osteopenia with or without a prevalent fracture.

KW - Osteopenia

KW - Strontium ranelate

KW - Vertebral fracture risk reduction

UR - http://www.scopus.com/inward/record.url?scp=39749127750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39749127750&partnerID=8YFLogxK

U2 - 10.1359/jbmr.071105

DO - 10.1359/jbmr.071105

M3 - Article

C2 - 17997711

AN - SCOPUS:39749127750

VL - 23

SP - 433

EP - 438

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 3

ER -